Stock Track | Organogenesis (ORGO) Plummets 5.12% as New Coverage Policy Raises Concerns

Stock Track

Nov 15, 2024

Shares of Organogenesis Holdings Inc. (ORGO) fell 5.12% in Friday's intraday trading, following the release of a new local coverage determination (LCD) by the Centers for Medicare & Medicaid Services (CMS) regarding skin substitute grafts and cellular tissue-based products for treating diabetic foot ulcers and venous leg ulcers.

While Organogenesis welcomed the evidence-based approach and the inclusion of its NuShield product in the covered list, investors appear concerned about the potential impact of the new policy on reimbursement levels and future revenue.

The company acknowledged that the LCD decision could affect coverage and reimbursement levels for its products, which has been a key risk factor in the past. As Organogenesis navigates this new policy landscape, investors will closely monitor its ability to maintain profitability and growth momentum.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1101049460"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101049460\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101049460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101049460","market":"hk","top_or_hot":-1,"title":"Stock Track | Organogenesis (ORGO) Plummets 5.12% as New Coverage Policy Raises Concerns","media":"Stock Track","content":"<p>Shares of Organogenesis Holdings Inc. (ORGO) fell 5.12% in Friday's intraday trading, following the release of a new local coverage determination (LCD) by the Centers for Medicare & Medicaid Services (CMS) regarding skin substitute grafts and cellular tissue-based products for treating diabetic foot ulcers and venous leg ulcers.</p>\n\n<p>While Organogenesis welcomed the evidence-based approach and the inclusion of its NuShield product in the covered list, investors appear concerned about the potential impact of the new policy on reimbursement levels and future revenue.</p>\n\n<p>The company acknowledged that the LCD decision could affect coverage and reimbursement levels for its products, which has been a key risk factor in the past. As Organogenesis navigates this new policy landscape, investors will closely monitor its ability to maintain profitability and growth momentum.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Organogenesis (ORGO) Plummets 5.12% as New Coverage Policy Raises Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Organogenesis (ORGO) Plummets 5.12% as New Coverage Policy Raises Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-15 23:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Organogenesis Holdings Inc. (ORGO) fell 5.12% in Friday's intraday trading, following the release of a new local coverage determination (LCD) by the Centers for Medicare & Medicaid Services (CMS) regarding skin substitute grafts and cellular tissue-based products for treating diabetic foot ulcers and venous leg ulcers.</p>\n\n<p>While Organogenesis welcomed the evidence-based approach and the inclusion of its NuShield product in the covered list, investors appear concerned about the potential impact of the new policy on reimbursement levels and future revenue.</p>\n\n<p>The company acknowledged that the LCD decision could affect coverage and reimbursement levels for its products, which has been a key risk factor in the past. As Organogenesis navigates this new policy landscape, investors will closely monitor its ability to maintain profitability and growth momentum.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ORGO","symbol_name":"Organogenesis Holdings Inc","start_time":0,"source_url":"","article_id":"1101049460","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101049460","pubTimestamp":1731685581,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Organogenesis Holdings Inc.  fell 5.12% in Friday's intraday trading, following the release of a new local coverage determination  by the Centers for Medicare & Medicaid Services  regarding skin substitute grafts and cellular tissue-based products for treating diabetic foot ulcers and venous leg ulcers.While Organogenesis welcomed the evidence-based approach and the inclusion of its NuShield product in the covered list, investors appear concerned about the potential impact of the new p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ORGO":"Organogenesis Holdings Inc"},"translate_title":"由于新的承保政策引发担忧，股票赛道Organogenesis(ORGO)暴跌5.12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORGO":1},"content_text":"Shares of Organogenesis Holdings Inc. (ORGO) fell 5.12% in Friday's intraday trading, following the release of a new local coverage determination (LCD) by the Centers for Medicare & Medicaid Services (CMS) regarding skin substitute grafts and cellular tissue-based products for treating diabetic foot ulcers and venous leg ulcers.\nWhile Organogenesis welcomed the evidence-based approach and the inclusion of its NuShield product in the covered list, investors appear concerned about the potential impact of the new policy on reimbursement levels and future revenue.\nThe company acknowledged that the LCD decision could affect coverage and reimbursement levels for its products, which has been a key risk factor in the past. As Organogenesis navigates this new policy landscape, investors will closely monitor its ability to maintain profitability and growth momentum.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}